KaloBios Pharmaceuticals
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
533 Airport Blvd Ste 400, Burlingame, Ca...Phone Number
(650) 243-3100Website
www.kalobios.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About KaloBios Pharmaceuticals
MEGA55 is an online gaming platform that offers modern slot games developed by Pragmatic Play, utilizing the latest server55 technology for optimal performance. The platform is designed to provide an engaging gaming experience with visually appealing graphics and easy-to-understand gameplay mechanics suitable for a wide range of players. MEGA55 ensures a smooth and responsive gaming experience, making it ideal for both beginners and seasoned players. With a focus on quality and stability, MEGA55 aims to deliver consistent and enjoyable online gaming sessions.Explore more
KaloBios Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is KaloBios Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if KaloBios Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if KaloBios Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once KaloBios Pharmaceuticals has new funding data
Product Launch: Get notified when KaloBios Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at KaloBios Pharmaceuticals
Earning: See what the market has to say on KaloBios Pharmaceuticals recently announced quarterly report
KaloBios Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if KaloBios Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at KaloBios Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to KaloBios Pharmaceuticals
Compare insights from companies similar to KaloBios Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
KaloBios Pharmaceuticals
$5.7M
11-50
Private
-
2001
MF
Mark FeuerbachTreasury, Financial Planning & Analysis Vice President, Investor Relations
Company Profile Activity
Activity Insights
KaloBios Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
KaloBios Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about KaloBios Pharmaceuticals.
KaloBios Pharmaceuticals Tech Stack
A closer look at the technologies used by KaloBios Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Pain Point
Bankruptcy
Pain Point
Bankruptcy
KaloBios Pharmaceuticals News & Media
Financings for Oct. 23, 2020
Eucrates Biomedical Acquisition Corp., of New York, reported the pricing of its IPO of 10 million units at a price of $10 per unit. The units will be listed on The Nasdaq Capital Market and trade under the ticker symbol EUCRU beginning Oct. 23. Each unit consists of one ordinary share of the company and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one ordinary share of the companyBe Biopharma launches with a $52M series A to develop engineered B-cell medicines
Be Biopharma Inc. is looking to develop engineered B cells to treat a wide range of diseases. The new category of cellular medicine is based on the work of David Rawlings and Richard James, researchers at Seattle Children’s Research Institute and the University of Washington.Aavantibio, with help from Sarepta, comes on with a $105M series A
Aavantibio Inc., with the help of a large check from Sarepta Therapeutics Inc., has launched with a $107 million series A to pursue gene therapies for treating rare genetic diseases. The lead program is in Friedreich’s ataxia (FA), a rare genetic disease that typically begins in childhood and causes progressive damage to the nervous system. Sarepta brings $15 million to Aavantibio’s table as an equity investment. Other investors of the new company include Perceptive Advisors,Financings for Oct. 22, 2020
Med-tech firms raising money in public or private financings, including: Cricket Health, Enviral Tech, Helius Medical Technologies, Invivo Therapeutics Holdings, Neodynamics.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding KaloBios Pharmaceuticals
Sign Up For FreeTo access detailed company insights
MEGA55 is an online gaming platform that offers modern slot games developed by Pragmatic Play, utilizing the latest server55 technology for optimal performance. The platform is designed to provide an engaging gaming experience with visually appealing graphics and easy-to-understand gameplay mechanics suitable for a wide range of players. MEGA55 ens... Read More
